<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
      <journal-title-group>
        <journal-title>BMC Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2407</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26354794</article-id>
      <article-id pub-id-type="pmc">4563835</article-id>
      <article-id pub-id-type="publisher-id">1620</article-id>
      <article-id pub-id-type="doi">10.1186/s12885-015-1620-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case report of severe Cushing&#x2019;s syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentration</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Hammami</surname>
            <given-names>Muhammad M.</given-names>
          </name>
          <address>
            <phone>+966-1-442-4527</phone>
            <email>Muhammad@kfshrc.edu.sa</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duaiji</surname>
            <given-names>Najla</given-names>
          </name>
          <address>
            <email>dr.duaiji@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mutairi</surname>
            <given-names>Ghazi</given-names>
          </name>
          <address>
            <email>almutairighazi@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aklabi</surname>
            <given-names>Sabah</given-names>
          </name>
          <address>
            <email>sabahalaklabi@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Qattan</surname>
            <given-names>Nasser</given-names>
          </name>
          <address>
            <email>alqattan98@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abouzied</surname>
            <given-names>Mohei El-Din M.</given-names>
          </name>
          <address>
            <email>MAboutaleb@kfshrc.edu.sa</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sous</surname>
            <given-names>Mohamed W.</given-names>
          </name>
          <address>
            <email>msous@kfshrc.edu.sa</email>
          </address>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Departments of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia </aff>
        <aff id="Aff2"><label>2</label>Departments of Clinical Studies and Empirical Ethics, King Faisal Specialist Hospital and Research Centre, P O Box # 3354 (MBC 03), Riyadh, 11211 Saudi Arabia </aff>
        <aff id="Aff3"><label>3</label>Departments of Radiology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia </aff>
        <aff id="Aff4"><label>4</label>Departments of Neurosciences, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>624</elocation-id>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>8</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Hammami et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Normalization of cortisol concentration by multikinase inhibitors have been reported in three patients with medullary thyroid cancer-related Cushing&#x2019;s syndrome. Aortic dissection has been reported in three patients with Cushing&#x2019;s syndrome. Diabetes insipidus without intrasellar metastasis, intestinal intussusception, and paraneoplastic dysautonomia have not been reported in medullary thyroid cancer.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>An adult male with metastatic medullary thyroid cancer presented with hyperglycemia, hypernatremia, hypokalemia, hypertension, acne-like rash, and diabetes insipidus (urine volume &gt;8&#xA0;L/d, osmolality 190&#xA0;mOsm/kg). Serum cortisol, adrenocorticoitropic hormone, dehydroepiandrostenedione sulfate, and urinary free cortisol were elevated 8, 20, 4.4, and 340 folds, respectively. Pituitary imaging was normal. Computed tomography scan revealed jejunal intussusception and incidental abdominal aortic dissection. Sorafenib treatment was associated with Cushing&#x2019;s syndrome remission, elevated progesterone (&gt;10 fold), normalization of dehydroepiandrostenedione sulfate, but persistently elevated cortisol concentration. Newly-developed proximal lower limb weakness and decreased salivation were associated with elevated ganglionic neuronal acetylcholine receptor (alpha-3) and borderline P/Q type calcium channel antibodies.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Extreme cortisol concentration may have contributed to aortic dissection and suppressed antidiuretic hormone secretion; which combined with hypokalemia due cortisol activation of mineralocorticoid receptors, manifested as diabetes insipidus. This is the first report of paraneoplastic dysautonomia and jejunal intussusception in medullary thyroid cancer, they may be related to medullary thyroid cancer&#x2019;s neuroendocrine origin and metastasis, respectively. Remission of Cushing&#x2019;s syndrome without measurable reduction in cortisol concentration suggests a novel cortisol-independent mechanism of action or assay cross-reactivity. Normalization of dehydroepiandrostenedione sulfate and elevation of progesterone suggest inhibition of 17-hydroxylase and 21-hydroxylase activities by sorafenib.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Cushing&#x2019;s syndrome (CS) refers to signs and symptoms caused by excessive glucocorticoids action through glucocorticoid and occasionally mineralocorticoid receptors. Ectopic adrenocorticotropic hormone (ACTH) secretion accounts for&#x2009;&lt;&#x2009;10&#xA0;% of CS; [<xref ref-type="bibr" rid="CR1">1</xref>] up to 7.5&#xA0;% of which are due to medullary thyroid cancer (MTC) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p>
      <p>Diabetes insipidus (DI) has been reported in two patients with ectopic CS and sellar metastasis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Although glucocorticoids can suppress antidiuretic hormone (ADH) secretion, DI has not been reported in CS without sellar lesions, possibly due to compensatory renal mechanisms [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>MTC arises from neuroendocrine calcitonin-producing parafollicular C cells of the thyroid gland; it ectopically secrets ACTH in about 0.6&#xA0;% of patients [<xref ref-type="bibr" rid="CR7">7</xref>]. Three case reports described successful treatment of ectopic CS in MTC patients with multikinase inhibitors; in all cases, CS remission was associated with reduction in cortisol concentration [<xref ref-type="bibr" rid="CR8">8</xref>&#x2013;<xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>Cardiovascular complications are rather common in CS; however, aortic dissection has been reported in only three cases [<xref ref-type="bibr" rid="CR11">11</xref>]. Intestinal intussusception is rare in adults and is secondary to a pathological condition in 90&#xA0;% of cases [<xref ref-type="bibr" rid="CR12">12</xref>]. It has not been reported in MTC patients. Paraneoplastic dysautonomia has been associated with neuroendocrine tumors other than MTC [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>We report a case of severe CS in a patient with metastatic MTC, which was complicated by DI without sellar lesion, silent aortic dissection, jejunal intussusception, and dysautonomia. Interestingly, sorafenib was associated with remission of CS without measurable reduction in cortisol concentration.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Case report</title>
        <p>A 30-year old male with MTC presented with 3-week history of severe polyuria, nocturia, polydipsia, salty taste, skin rash, insomnia, and delusion. He denied vomiting, diarrhea, pain, dyspnea, cough, and fever.</p>
        <p>He was referred about 4.5&#xA0;years earlier after having total thyroidectomy that showed multifocal MTC with cervical lymph nodes metastasis. His past medical and surgical history was otherwise unremarkable. He had no family history of MTC, other tumors, or consanguinity, and negative screening for pheochromocytoma, hyerparathyroidism, and germline RET (rearranged during transfection) oncogene mutation. Calcitonin and carcinoembryonic antigen (CEA) were &gt;5850 pmol/L (normal, &lt;5.5) and 506&#xA0;&#x3BC;g/L (normal, &lt;4.3), respectively. Over the following year, he underwent bilateral neck dissection for extensive regional lymph node metastasis followed by external radiation. Computed tomography (CT) scan showed normal liver and bilateral pulmonary metastases. Calcitonin and CEA decreased to 1430 pmol/L and 287&#xA0;&#x3BC;g/L and then increased to 5290 pmol/L and 544&#xA0;&#x3BC;g/L, respectively, 4&#xA0;months prior to admission. One year before admission, random glucose was 5.22&#xA0;mmol/L.</p>
        <p>On admission (day one), he was afebrile and appeared severely dehydrated. Pulse was 125/min, blood pressure 145/90&#xA0;mmHg (previous readings, 100&#x2013;110/65&#x2013;75), and body mass index 20.9&#xA0;kg/m<sup>2</sup>. He had multiple facial erythematous papules and few pustules but no moon face, centripetal obesity, supraclavicular fullness, cervical fat pad, striae, easy bruising, or stigmata of chronic liver disease except for non-tender hepatomegaly. He had normal muscle power and deep tendon reflexes. White blood cell (WBC) count was 21.7&#xD7;10<sup>9</sup>/L (80&#xA0;% neutrophils), creatinine 52&#xA0;&#x3BC;mol/L (normal, &lt;115), potassium 2.1&#xA0;mmol/L (normal, 3.5&#x2013;5.0), sodium 148&#xA0;mmol/L (normal, 135&#x2013;147), CO<sub>2</sub> 27&#xA0;mmol/L (normal, 22&#x2013;31), glucose 25.7&#xA0;mmol/L, albumin 35&#xA0;g/L (normal, 32&#x2013;48), total bilirubin 12&#xA0;&#x3BC;mol/L (normal, &lt;21), alanine aminotransaminase (ALT) 199 U/L (normal, 10&#x2013;45), aspartate aminotransferase (AST) 117 U/L (normal, 10&#x2013;45), alkaline phosphatase 216 U/L (normal, 40&#x2013;135), venous blood pH&#xA0;7.49 (normal, 7.30&#x2013;7.40), CEA 3643&#xA0;&#x3BC;g/L, calcitonin 1800 pmol/L, and glycated hemoglobin 0.07 (normal, &lt;0.065). Insulin, intravenous fluid and potassium replacement, enoxaparin 40&#xA0;mg/d, and topical acne treatment were started, and levothyroxine 150&#xA0;&#x3BC;g, vitamin D3 2000 unit, and calcium carbonate 1200&#xA0;mg daily were continued.</p>
        <p>Urine output was consistently &gt;8&#xA0;L/d, while plasma and urine osmolality were 296/310 (normal, 275&#x2013;300) and 189/190&#xA0;mOsm/kg, respectively; and sodium, potassium, glucose, and urea 154/148, 2.9/2.8, 21.5/14.5, and 2.6/2.3 (normal, 4.2&#x2013;4.2) mmol/L, respectively. Intranasal desmopressin (DDAVP) 40&#xA0;&#x3BC;g/d reduced urine output to 4.85&#xA0;L/d (sodium, potassium, and glucose were 149, 3.5, and 12.1&#xA0;mmol/L, respectively).</p>
        <p>On day 5, cortisol and ACTH were 3782&#xA0;nmol/L (normal, 171&#x2013;536) and 872&#xA0;ng/L (normal, 5&#x2013;60; to convert to pmol/L multiply by 0.22), respectively, urinary free cortisol 129,204 nmo (normal, 100&#x2013;379), dehydroepiandrostenedione sulfate (DHEAS) 50.8&#xA0;&#x3BC;mol/L (normal, 4.42&#x2013;11.50), dehydroepiandrostenedione (DHEA) 12&#xA0;ng/mL (Mayo Medical Laboratories (MML), Mayo Clinic, Rochester, MN; normal, &lt;13; to convert to nmol/L multiply by 3.47), androstendione &gt;35&#xA0;nmol/L (normal, 2.4-12.6), renin 19.6&#xA0;mU/L (normal, 4.4&#x2013;46.1), and aldosterone&#x2009;&lt;&#x2009;8&#xA0;ng/dL (MML; normal, &lt; 21; to convert to nmol/L multiply by 0.277). 8-mg dexamethasone suppression test showed a paradoxical increase in cortisol to 4279&#xA0;nmol/L. Urinary potassium was &gt;100&#xA0;mmol/d with plasma potassium of 3.3&#xA0;mmol/L.</p>
        <p>CT scan showed 1.8&#xA0;cm pretracheal lymph node, bilateral hilar lymphadenopathy, 1.4&#xA0;cm left paracardiac lymph node, progression of lung metastases bilaterally (largest 3&#xA0;cm), new liver metastases (largest 5x5 cm with central necrosis and hemorrhage), enlarged adrenal glands (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>), and short segment of dissection in abdominal aorta with thrombosed false lumen (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). Aortic dissection was managed conservatively by enoxaparin and blood pressure control. Fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT scan showed multiple hypermetabolic liver and lung lesions and diffuse bilateral hypermetabolic adrenal activity (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). Pituitary magnetic resonance imaging (MRI) was normal (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Major radiological findings. <bold>a</bold> Trans axial images of enhanced computed tomography (CT) of the abdomen showing: hypodense liver lesions in both lobes (the largest is located in segment IV adjacent to porta hepatis, white arrow), and bilateral adrenal hyperplasia (black arrows). <bold>b</bold> Aortic dissection below the level of renal arteries (white arrow head) extending to the left and right common iliac arteries (white arrows). <bold>c</bold> FDG PET-CT scan showing multiple hyper metabolic liver lesions (white arrow head), lung metastasis involving the left paracardiac area (black arrow), and diffuse bilateral hyper metabolic activity within the adrenal gland (white arrows). <bold>d</bold> Sagittal and axial (post contrast) T1 weighted MRI images showing normal pituitary gland. <bold>e</bold> Trans axial image of enhanced computed CT of the abdomen showing jeujenal intussusception</p></caption><graphic xlink:href="12885_2015_1620_Fig1_HTML" id="d30e536"/></fig></p>
        <p>Escalating doses of insulin (up to 87 U/d), spironolactone (up to 450&#xA0;mg/d), oral and intravenous potassium (up to 340&#xA0;mmol/d), amlodipine (up 10&#xA0;mg/d), and carvedilol (up to 25&#xA0;mg/d) were required to control CS (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>&amp;<xref rid="Fig2" ref-type="fig">b</xref>). Adrenalectomy was not offered because of aortic dissection/thrombosis necessitating anticoagulation. Ketoconazole and mitotane were not used because of liver dysfunction, and metyrapone because of severe hypokalemia. Sorafinib 400&#xA0;mg twice daily was started on day 10 (vandetanib and cabozantinib were unavailable). DDAVP was stopped because it may stimulate ectopic ACTH secretion; four days later, urine output increased to 7.8&#xA0;L/d with ADH of 3.3&#xA0;pg/mL (MML; normal, 0.0-6.9; to convert to pmol/L multiply by 0.926), plasma and urine osmolality of 311 and 522&#xA0;mOsm/kg, respectively, and sodium, potassium, and glucose of 149, 3.5, and 14.8&#xA0;mmol/L, respectively.<fig id="Fig2"><label>Fig. 2</label><caption><p>Main treatments and clinical and laboratory findings over the course of hospitalization. <bold>a</bold> Daily doses of spironolactone (mg, open triangles), sorafenib (mg, closed triangles), mifepristone (mg, closed squares), potassium chloride (mmol potassium, open squares), and insulin (units, open circles). <bold>b</bold> Daily doses of carvedilol (mg, open squares) and amlodipine (mg, closed squares). <bold>c</bold> Concentrations of cortisol (nmol/L, closed squares), carcinoembryonic antigen (CEA, &#x3BC;g/L, open squares), calcitonin (pmol/L, closed circles), adrenocorticoitropic hormone (ACTH, ng/L, open circles; values greater than 2000&#xA0;ng/dL are reported as 2000&#xA0;ng/L; multiply by 0.22 to convert to pmol/L), and renin (mU/L, closed triangles). Aldosterone was&#x2009;&lt;&#x2009;8 and&#x2009;&lt;&#x2009;4&#xA0;ng/L (multiply by 0.277 to convert to nmol/L) on days 5 and 36, respectively. <bold>d</bold> Mean daily concentration of sodium (mmol/L, closed triangles), mean daily measurements of systolic (mmHg, open triangles) and diastolic blood pressure (mmHg, open squares), and concentration of dehydroepiandrosterone sulfate (DHEAS, closed squares, &#x3BC;mol/L). Dehydroepiandrosterone (DHEA) was 12 and 3.9&#xA0;ng/mL on days 8 and 25, respectively (multiply by 3.47 to convert to nmol/L). Progesterone was 40.4 and 42.2&#xA0;nmol/L on days 40 and 43, respectively. 17-hydroxyprogestrone was 6.2&#xA0;nmol/L on day 40. <bold>e</bold> Mean daily concentration of glucose (mmol/L, closed squares) and potassium (mmol/L, open squares). <bold>f</bold> Concentrations of alkaline phosphatase (U/L, closed squares), alanine aminotransaminase (ALT, U/L, open squares), aspartate aminotransferase (AST, U/L, open circles), and total bilirubin (&#x3BC;mol/L, closed circles). Prothrombin time was 15.4, 17.4, 22.1, 31.5, and 37.6&#xA0;s on days 16, 27, 36, 43, 48, respectively. Albumin was 35, 32, and 19.7&#xA0;g/L on days 1, 21, and 41, respectively</p></caption><graphic xlink:href="12885_2015_1620_Fig2_HTML" id="d30e572"/></fig></p>
        <p>On day 15, he developed dyspnea, cough, mild hemoptysis, and oxygen desaturation without fever. Echocardiography was normal. CT scan showed no evidence of pulmonary embolism and new diffuse bronchial-wall thickening and multiple patchy ground-glass opacities. WBC was 13.6&#xD7;10<sup>9</sup> (94&#xA0;% neutrophils). Sputum culture was positive for streptococcus pneumonia. Procalcitonin concentration was 110&#xA0;ng/mL (normal, &lt;0.5; severe bacterial infection, &gt;2.0). He was treated vancomycin followed by ceftriaxone (till day 42). <sup>99m</sup>Tc-Octreotide scan revealed that the liver and lung lesions were not octreotide avid.</p>
        <p>On day 20, because of no measurable changes in ACTH and cortisol concentrations and development of proximal lower limb weakness (could get up from chair unassisted with difficulty), mifepristone 300&#xA0;mg/d was started. At that time, blood pressure was 141/89&#xA0;mmHg and sodium, potassium, and glucose 151, 3.6, and 7.8&#xA0;mmol/L, respectively.</p>
        <p>On day 25, CEA concentration decreased to 3019&#xA0;&#x3BC;g/L, calcitonin to 1530 pmol/l (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>), DHEAS to 23.96&#xA0;&#x3BC;mol/L (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2d</xref>), and DHEA to 3.9&#xA0;ng/ml (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). Further, blood pressure normalized to 118/78&#xA0;mmHg and sodium, potassium, and glucose to 145, 4.3, and 7.5&#xA0;mmol/L, respectively (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2d</xref>&amp;<xref rid="Fig2" ref-type="fig">e</xref>). However, cortisol and ACTH did not decrease (3911&#xA0;nmol/L, 1664&#xA0;ng/L, respectively) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>), and androstenedione continued to be &gt;35&#xA0;nmol/L. Renin was 22.1&#xA0;mU/L.</p>
        <p>On day 27, he complained of intermittent colicky abdominal pain increasing in severity and frequency, loss of appetite, and generalized fatigability in association with low normal blood pressure and glucose despite reducing insulin and amlodipine doses. Procalcitonin concentration was 281&#xA0;ng/ml. Adrenal insufficiency was suspected, mifepristone discontinued, and intravenous dexamethasone given for 5&#xA0;days (initially 8&#xA0;mg/d) without remarkable improvement. The abdominal pain was treated with fentanyl patch supplemented with intravenous morphine. CT scan showed bilateral pleural effusion, reduction in the left paracardiac lymph node to 1&#xA0;cm with central necrosis, mild reduction in the size of liver metastases, ascites, patent portal vein, no evidence of biliary dilatation, no change in the appearance of aortic dissection or adrenal glands, and jejuno-jejunal intussusception (Fig. <xref rid="Fig1" ref-type="fig">1e</xref>) with fecal loading without evidence of bowel obstruction.</p>
        <p>On day 34, proximal lower limb weakness progressed to the degree that he was bed-bound, despite remarkable control of CS manifestations (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>-<xref rid="Fig2" ref-type="fig">e</xref>), and was associated with loss of deep tendon reflexes. There was no muscle pain, tenderness, atrophy, or post-exercise facilitation. Electrolytes were normal. The unexplained weakness together with the development of difficulty in swallowing due to reduced salivation (requiring saliva substitute every four hours, modified barium swallow evaluation was normal), difficulty in urination, constipation, and rather unexplained postural tachycardia prompted investigations for neurological autoimmunity. A paraneoplastic autoantibody screen revealed elevated neuronal ganglionic acetylcholine (alpha-3) autoantibodies of 0.12&#xA0;nmol/L and borderline P/Q type calcium channel autoantibodies of 0.02&#xA0;nmol/L (MML; normal, &lt;0.02), consistent with autoimmune dysautonomia. Nerve conduction and repetitive nerve stimulation studies were unremarkable (23&#xA0;% amplitude increment with 30 stimuli/s). Electromyography of the right anterior tibial and vastus medialis muscles showed reduction in mean amplitude (0.13 and 0.15&#xA0;mV, normal 0.22 and 0.23&#xA0;mV, respectively) and duration (8.5 and 8.8&#xA0;ms, normal 13.1 and 10.9&#xA0;ms, respectively). 25 Hydroxyvitamin D was 15&#xA0;nmol/L, free T4 6.4 pmol/L (normal, 12&#x2013;22), thyroid stimulating hormone (TSH) 1.27&#xA0;mU/L (normal, 0.27&#x2013;4.20), and parathyroid hormone (PTH) 20.5&#xA0;ng/L (normal, 15&#x2013;65; to convert to pmol/L multiply by 0.1061).</p>
        <p>Despite persistently elevated ACTH and cortisol, starting on day 20, insulin and potassium doses had to be tapered off to avoid hypoglycemia and hyperkalemia (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>&amp;<xref rid="Fig2" ref-type="fig">e</xref>). Further, mifepristone which was restarted on day 34 at 200&#xA0;mg/d had to be decreased to 100&#xA0;mg/d after 7&#xA0;days to be stopped 2&#xA0;days later (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). Similarly, starting on day 30, amlodipine and carvedilol had to be tapered off to avoid hypotension (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>). Spironolactone was reduced gradually to 100&#xA0;mg/d on day 41 (continued for ascites and lower limb edema) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). By day 31, urine output normalized and he had mild hyponatremia. On day 37, ADH was 3.9&#xA0;pg/ml, plasma and urine osmolality 284 and 552&#xA0;mOsm/kg, respectively, and sodium, potassium, glucose, and urea 133, 4.8, 5.33, and 5.7&#xA0;nmol/L, respectively. Renin increased to 385 and 757&#xA0;mU/L on days 37 and 46, respectively (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref>). DHEAS decreased to 9.85&#xA0;&#x3BC;mol/L on day 46 (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2d</xref>). On day 40, progesterone and 17-hydroxyprogestrone concentrations were 40.4&#xA0;nmol/L (normal for adult males, 0.7&#x2013;4.3) and 6.2&#xA0;nmol/L, respectively. On day 43 progesterone was 42.2&#xA0;nmol/L. To verify the persistently elevated cortisol, a split sample was sent to another laboratory (competitive binding immunoenzymatic assay, MML). Cortisol was 4170&#xA0;nmol/L in our laboratory and 114&#xA0;&#x3BC;g/dL (normal, 7&#x2013;25; to convert to nmol/L multiply by 27.6) in the other, representing 7.8 vs. 4.6 fold increase over upper limits, respectively.</p>
        <p>Liver function tests deteriorated sequentially, starting with an increase in alkaline phosphatase and total (direct) bilirubin followed by a decrease in albumin, prolongation of prothrombin time, and an increase in ALT and AST (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2f</xref>). Screening for hepatitis A, B, and C was negative. Liver US/Doppler showed enlarged liver studded with metastatic disease, patent main portal vein with sluggish flow, flow reversal within the left portal and splenic veins, and no biliary dilatation.</p>
        <p>On day 42, he had desaturation, sputum grew pseudomonas, and procalcitonin was &gt;500&#xA0;ng/ml. Sorafenib and mifepristone were stopped and intravenous dexamethasone was given. Liver function tests continued to deteriorate and hemoglobin dropped to 87&#xA0;g/L. He died on day 49 due to cardiopulmonary arrest despite intravenous antibiotics and fresh frozen plasma, red blood cell, and albumin infusions.</p>
        <p>Laboratory investigations were performed by our Department of Pathology and Laboratory Medicine except as indicated. Cortisol, ACTH, and DHEAS were measured by electrochemiluminescence immunoassay (Elecsys cortisol, ACTH, DHEAS kits, respectively, Roche Diagnostics, Indianapolis, IN) on cobas e analyzer following manufacturer&#x2019;s specifications. Androstenedione was measured by solid-phase enzyme-labeled chemiluminescence immunoassay (DPC Immulite andorostenedione kit, Diagnostic Products Corporation, Los Angeles, CA) on DPC automated immunoassay system following manufacturer&#x2019;s specifications.</p>
      </sec>
    </sec>
    <sec id="Sec4">
      <title>Discussion</title>
      <p>The unique features of this unfortunate case of sporadic MTC and ectopic ACTH CS include: 1) exceedingly elevated urinary free cortisol, 2) reversible combined neurogenic and nephrogenic DI, 3) CS remission with sorafenib without measurable reduction in cortisol concentration, 4) abdominal aortic dissection, 5) jejuno-jejunal intussusception, 6) development of autoantibodies against neuronal ganglionic acetylcholine receptor, and 7) development of acute liver failure.</p>
      <p>CS refers to signs and symptoms caused by excessive glucocorticoids action through glucocorticoid and occasionally mineralocorticoid receptors. Ectopic CS occurs in 0.6&#xA0;% of MTC patients, usually with advanced disease [<xref ref-type="bibr" rid="CR7">7</xref>]. As expected, our patient had liver and lung metastasis and markedly elevated tumor markers. However, his exceedingly high serum cortisol and urinary free cortisol were unusual. Further, despite florid derangements related to activation of mineralocorticoid and androgen receptors, hyperglycemia was the only glucocorticoid receptor-related abnormality. Having normoglycemia prior to admission and normal BMI and mildly elevated glycated hemoglobin on admission, indicated that the hyperglycemia was CS-induced and suggested that the other glucocorticoid receptor-related manifestations of CS may take longer time to develop. Severe hypokalemia and hyperkaliuria were likely due to activation of mineralocorticoid receptors by elevated cortisol that evaded inactivation by 11-beta-hydroxysteroid dehydrogenase.</p>
      <p>The polyuria in our patient was not explained by hyperglycemia as it persisted after its correction and was associated with low urine osmolality. Further, the degree and persistence of polyuria were more than expected from the degree of hypokalemia, suggesting a neurogenic DI component. This was confirmed by a partial response to DDAVP, recurrence after stopping DDAVP, and an ADH that was inappropriately in the low normal range. DI was reported in two MTC patients without CS [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] and in two patients with small-cell lung cancer and CS [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In all cases there was intrasellar metastasis. Pituitary MRI in our patient was normal, suggesting functional neurogenic DI. As little as 30&#xA0;mg prednisolone for 5&#xA0;days inhibited osmotically-stimulated ADH secretion, however, urine osmolar concentration was unaffected; perhaps due to ADH-independent renal compensatory mechanisms [<xref ref-type="bibr" rid="CR6">6</xref>]. We postulate that elevated cortisol in our patient caused ADH suppression and hypokalemia prevented the proposed compensatory mechanisms. Interestingly, after blocking cortisol action and correction of hypokalemia, urine output normalized and mild hyponatremia developed.</p>
      <p>This is the first reported case of failure of elevated cortisol to decrease in MTC-related CS treated with multikinase inhibitors. In the two cases treated with vandetanib [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] and one case treated with sorafenib [<xref ref-type="bibr" rid="CR10">10</xref>], cortisol normalized within a week. Nevertheless, CS was reversed in our patient, necessitating discontinuation of the previously-required, large doses of potassium, spironolactone, antihypertensives, and insulin. Although mifepristone may have played a role in diabetes mellitus remission, it could not explain remission of hypertension and hypokalemia, its dose was relatively small, and diabetes mellitus remission persisted despite its withdrawal.</p>
      <p>The mechanisms underlying reduction of cortisol concentration in this setting may be multifactorial. In one case, vandetanib resulted in simultaneous decrease in cortisol and calcitonin and a blunted response of ACTH to DDAVP without reduction in tumor size, suggesting a direct antisecretory action [<xref ref-type="bibr" rid="CR8">8</xref>]. In another case, sorafenib reduced cortisol and ACTH with modest reduction in calcitonin and CEA, suggesting a selective inhibition of ACTH and cortisol secretion; reduction in POMC mRNA expression through MAPK pathway inhibition, ACTH action down-regulation by downstream signaling pathway inhibition, and adrenal ischemia were postulated [<xref ref-type="bibr" rid="CR10">10</xref>]. In the third case, vandetanib resulted in sustained (26&#xA0;months) normalization of cortisol and ACTH. However, a mild re-increase in ACTH without an increase in cortisol occurred while on vandetanib [<xref ref-type="bibr" rid="CR9">9</xref>]. In our patient, there was a remarkable decrease in DHEAS and elevation in progesterone, suggesting a direct adrenal action of sorafenib, namely, 21-hydroxylase and 17-hydroxylase inhibition. Progesterone exhibits the same affinity as aldosterone for the human mineralocorticoid receptor, acting as antagonist [<xref ref-type="bibr" rid="CR16">16</xref>]. It has antagonistic activity at the glucocorticoid receptor especially with reduced receptors number [<xref ref-type="bibr" rid="CR17">17</xref>]. Despite &gt;10 fold increase, progesterone would not effectively compete with prevailing cortisol in our patient, since both are equally protein-bound [<xref ref-type="bibr" rid="CR16">16</xref>]. Nevertheless, we could not exclude a role of progesterone in CS remission because of the possibility of spuriously high cortisol concentration. For example, 21-deoxycortisol, which is elevated by 21-hydroxylase inhibition, had 45&#xA0;% cross-reactivity in our cortisol immunoassay [<xref ref-type="bibr" rid="CR18">18</xref>]. Further, cortisol concentration was increased 7.8 fold over upper normal limit in our immunoassay compared to 4.6 fold in another immunoassay. Much to our regret, we did not measure cortisol concentration by a more specific liquid chromatography assay or 21-deoxycortisol concentration. Finally, sorafenib was shown to down regulate wild type and c-terminally truncated (lacking ligand binding domain) androgen receptors in prostate cancer cells and to inhibit their signaling [<xref ref-type="bibr" rid="CR19">19</xref>]. We postulate a similar action of sorafenib on mineralocorticoid and glucocorticoid receptors in our patient. It is of note that insulin-independent hypoglycemia was induced by sorafenib in a patient with hemangiopericytoma and was responsive to glucocorticoid treatment [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
      <p>Aortic dissection has been reported in 3 men with CS, two with adrenal adenoma and one with pituitary adenoma; all three presented with dissection-related symptoms [<xref ref-type="bibr" rid="CR11">11</xref>]. In our patient, aortic dissection was discovered accidently. The prevalence of silent aortic dissection in CS is not known as most cases of CS are due to exogenous glucocorticoids or Cushing&#x2019;s disease and abdominal imaging is not performed. A causal relationship between elevated cortisol and aortic dissection can be postulated; cortisol could increase blood vessels fragility through negative effects on collagen formation and connective tissue strength. Acute elevation in blood pressure is another potentially contributing factor.</p>
      <p>Intestinal intussusception in adults is rare accounting for 5&#xA0;% of all intussusceptions; most cases are secondary to lead lesions requiring surgical intervention; and presenting symptoms are usually chronic and nonspecific [<xref ref-type="bibr" rid="CR12">12</xref>]. To the best of our knowledge, intestinal intussusception has not been reported in MTC, nor has intestinal metastasis. We postulate that the intussusception was the cause of the intermittent abdominal pain in our patient and that it was likely due to metastasis, however, functional intussusception cannot be excluded as a mass was not visualized.</p>
      <p>Lambert-Eaton syndrome (LES), a rare neuromuscular transmission disorder, characterized by proximal muscle weakness, depressed deep tendon reflexes, post-tetanic potentiation, and autonomic dysfunction, is caused by autoimmunity against P/Q voltage-gated calcium channel [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. It is most commonly associated with small-cell lung cancer but has not been reported in MTC [<xref ref-type="bibr" rid="CR22">22</xref>]. Our patient presented with normal power despite having profound hypokalemia and hypercortisolemia, started to have mild weakness 20&#xA0;days later when hypokalemia was corrected, and his weakness rapidly progressed to the degree that he became bed-bound despite mifepristone treatment. Electrolytes and TSH were normal. 25- Hydroxyvitamin D concentration was low, however, this was likely due to low binding proteins since PTH and corrected calcium were normal, and he had been on 2000 U of vitamin D daily. Absence of deep tendon reflexes, markedly decreased salivation, and postural tachycardia suggested LES and autoimmune dysautonomia. We could not confirm LES diagnosis since repetitive stimulation testing was negative and P/Q voltage-gated calcium channel antibodies were only upper normal. However, electromyography revealed motor unit potentials of short duration and decreased amplitude as described in LES [<xref ref-type="bibr" rid="CR23">23</xref>] and neuronal ganglionic acetylcholine receptor autoantibodies, the only proven effector of autoimmune dysautonomia [<xref ref-type="bibr" rid="CR13">13</xref>], were markedly elevated; which to our knowledge has not been described in MTC.</p>
      <p>Another challenge we encountered in managing the patient was related to using procalcitonin to diagnose bacterial infection. Elevated procalcitonin, in general, indicates bacterial infection [<xref ref-type="bibr" rid="CR24">24</xref>]. However, procalcitonin was useless in our patient since it is elevated in MTC patients [<xref ref-type="bibr" rid="CR25">25</xref>] and may be elevated in adrenal crisis [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>About 50&#xA0;% of sporadic MTC carry RET gene somatic mutations, and RAS mutations are observed in about 50&#xA0;% of RET-negative tumors [<xref ref-type="bibr" rid="CR27">27</xref>]. The multikinase inhibitors, vandetanib and cabozantinib, were recently approved to treat symptomatic or progressive MTC [<xref ref-type="bibr" rid="CR10">10</xref>]. Sorafenib was investigated in Phase II trials [<xref ref-type="bibr" rid="CR28">28</xref>] and was successfully used to treat CS in MTC [<xref ref-type="bibr" rid="CR10">10</xref>]. Since vandetanib and cabozantinib were not available in our institution, we treated our patient with sorafenib. There was an initial 15&#xA0;% decrease in calcitonin and CEA and regression in some of the liver and lymph node metastasis within 17&#xA0;days of treatment, however, calcitonin and CEA quickly rebounded and liver metastasis progressed.</p>
      <p>Acute liver failure, characterized by the development of jaundice, coagulopathy, and hepatic encephalopathy within 8&#xA0;weeks in the absence of preexisting liver disease, was reported in a patient with liver metastasis from MTC [<xref ref-type="bibr" rid="CR29">29</xref>]. Liver functions in our patient deteriorated rapidly over 7&#xA0;weeks, while screening tests for hepatitis A, B, and C were negative. Although iatrogenic liver injury due to sorafenib could not be excluded, it is likely that progression of liver metastasis was the culprit as suggested by the results of hepatic ultrasound/Doppler results. Further, mild liver test abnormalities have been reported in &lt;1&#xA0;% of sorafenib treated patients, and severe acute hepatitis is very rare, usually of the hepatocellular type, and is associated with high fever and rash; [<xref ref-type="bibr" rid="CR30">30</xref>] which was not the case in our patient.</p>
    </sec>
    <sec id="Sec5">
      <title>Conclusions</title>
      <p>Extremely elevated cortisol may have contributed to aortic dissection, due to interference with collagen formation, and suppressed ADH secretion; which combined with hypokalemia due cortisol activation of the mineralocorticoid receptors, manifested as reversible combined neurogenic and nephrogenic DI. Paraneoplastic dysautonomia and jejunal intussusception have not been reported in MTC, they may be related to MTC&#x2019;s neuroendocrine origin and metastasis, respectively. Remission of CS with sorafenib without measurable reduction in cortisol concentration suggests a novel cortisol-independent mechanism of action, such as down regulation of glucocorticoid and mineralocorticoid receptors or inhibition of their signaling. Alternatively, normalization of DHEAS and elevation of progesterone concentration suggest inhibition of 17-hydroxylase and 21-hydroxylase activities. The later could result in elevated 21-deoxycortisol that may be spuriously measured as cortisol in immunoassays. In addition, progesterone could block glucocorticoid and mineralocorticoid receptors depending on actual cortisol concentration. Further studies are required to explore potential effects of multikinase inhibitors on adrenal steroids synthesis and action, the prevalence of silent aortic dissection in CS, and the prevalence of paraneoplastic dyasautonomia in MTC.</p>
    </sec>
    <sec id="Sec6">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient next of kin for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CS</term>
          <def>
            <p>Cushing&#x2019;s syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>ACTH</term>
          <def>
            <p>adrenocorticotropic hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>MTC</term>
          <def>
            <p>Medullary thyroid cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>DI</term>
          <def>
            <p>Diabetes insipidus</p>
          </def>
        </def-item>
        <def-item>
          <term>ADH</term>
          <def>
            <p>Antidiuretic hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>RET</term>
          <def>
            <p>Rearranged during transfection</p>
          </def>
        </def-item>
        <def-item>
          <term>CEA</term>
          <def>
            <p>Carcinoembryonic antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>Computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>WBC</term>
          <def>
            <p>White blood cell</p>
          </def>
        </def-item>
        <def-item>
          <term>ALT</term>
          <def>
            <p>Alanine aminotransaminase</p>
          </def>
        </def-item>
        <def-item>
          <term>AST</term>
          <def>
            <p>Aspartate aminotransferase</p>
          </def>
        </def-item>
        <def-item>
          <term>DDAVP</term>
          <def>
            <p>Desmoprssin</p>
          </def>
        </def-item>
        <def-item>
          <term>DHEAS</term>
          <def>
            <p>Dehydroepiandrostenedione sulfate</p>
          </def>
        </def-item>
        <def-item>
          <term>MML</term>
          <def>
            <p>Mayo Medial Laboratories</p>
          </def>
        </def-item>
        <def-item>
          <term>DHEA</term>
          <def>
            <p>Dehydroepiandrostenedione</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>Magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>FDG</term>
          <def>
            <p>Fluorodeoxyglucose</p>
          </def>
        </def-item>
        <def-item>
          <term>PET</term>
          <def>
            <p>Positron emission tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>TSH</term>
          <def>
            <p>Thyroid stimulating hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>PTH</term>
          <def>
            <p>Parathyroid hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>DPC</term>
          <def>
            <p>Diagnostic products corporation</p>
          </def>
        </def-item>
        <def-item>
          <term>POMC</term>
          <def>
            <p>Proopiomelanocortin</p>
          </def>
        </def-item>
        <def-item>
          <term>MAPK</term>
          <def>
            <p>Mitogen-activated protein kinase</p>
          </def>
        </def-item>
        <def-item>
          <term>LES</term>
          <def>
            <p>Lambert-Eaton syndrome</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>MMH performed literature review and wrote the manuscript. ND, GM, SA, NQ and MWS participated in literature review. MMA prepared radiological images. All authors were involved in the management of the patient. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgment</title>
      <p>This work was supported by King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boscaro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arnaldi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Approach to the patient with possible Cushing&#x2019;s syndrome</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2009</year>
          <volume>94</volume>
          <fpage>3121</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2009-0612</pub-id>
          <pub-id pub-id-type="pmid">19734443</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isidori</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Kaltsas</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Pozza</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Frajese</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Newell-Price</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Reznek</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Monson</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Besser</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow up</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2006</year>
          <volume>91</volume>
          <issue>2</issue>
          <fpage>371</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2005-1542</pub-id>
          <pub-id pub-id-type="pmid">16303835</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ilias</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Torpy</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Pacak</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mullen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wesley</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Nieman</surname>
              <given-names>LK</given-names>
            </name>
          </person-group>
          <article-title>Cushing&#x2019;s syndrome due to ectopic corticotropin secretion: twenty years&#x2019; experience at the National Institutes of Health</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2005</year>
          <volume>90</volume>
          <issue>8</issue>
          <fpage>4955</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2004-2527</pub-id>
          <pub-id pub-id-type="pmid">15914534</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Asa</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Fuller</surname>
              <given-names>GN</given-names>
            </name>
          </person-group>
          <article-title>Medullary thyroid carcinoma metastatic to the pituitary gland: an unusual site of metastasis</article-title>
          <source>Ann Diagn Pathol</source>
          <year>2008</year>
          <volume>12</volume>
          <fpage>199</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="doi">10.1016/j.anndiagpath.2006.08.007</pub-id>
          <pub-id pub-id-type="pmid">18486896</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santarpia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gagel</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Sarlis</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Hoff</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
          <article-title>Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer</article-title>
          <source>Head Neck</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>419</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1002/hed.20911</pub-id>
          <pub-id pub-id-type="pmid">18798312</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ba&#xA8;hr</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Franzen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Oelkers</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Pfeiffer</surname>
              <given-names>AFH</given-names>
            </name>
            <name>
              <surname>Diederich</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Effect of exogenous glucocorticoid on osmotically stimulated antidiuretic hormone secretion and on water reabsorption in man</article-title>
          <source>Eur J Endocrinol</source>
          <year>2006</year>
          <volume>155</volume>
          <fpage>845</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.1.02299</pub-id>
          <pub-id pub-id-type="pmid">17132754</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barbosa</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Rodien</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leboulleux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Niccoli-Sire</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kraimps</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Caron</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Archambeaud-Mouveroux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Conte-Devolx</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rohmer</surname>
              <given-names>V</given-names>
            </name>
            <collab>Groupe d&#x2019;Etude des Tumeurs Endocrines</collab>
          </person-group>
          <article-title>Ectopic adrenocorticotropic hormone &#x2013;syndrome in medullary carcinoma of the thyroid: a retrospective analysis and review of the literature</article-title>
          <source>Thyroid</source>
          <year>2005</year>
          <volume>15</volume>
          <issue>6</issue>
          <fpage>618</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="doi">10.1089/thy.2005.15.618</pub-id>
          <pub-id pub-id-type="pmid">16029131</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baudry</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Paepegaey</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Groussin</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Reversal of Cushing&#x2019;s syndrome by vandetanib in medullary thyroid carcinoma</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>369</volume>
          <fpage>584</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc1301428</pub-id>
          <pub-id pub-id-type="pmid">23924025</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nella</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Lodish</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Balis</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Quezado</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Whitcomb</surname>
              <given-names>PO</given-names>
            </name>
            <name>
              <surname>Derak</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kebebew</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Widemann</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Stratakis</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2014</year>
          <volume>99</volume>
          <fpage>3055</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2013-4340</pub-id>
          <pub-id pub-id-type="pmid">24617713</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barroso-Sousa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lerario</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Evangelista</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Papadia</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lourenc</surname>
              <given-names>DM</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Kulcsar</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Fragoso</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Hoff</surname>
              <given-names>AO</given-names>
            </name>
          </person-group>
          <article-title>Complete resolution of hypercortisolism with sorafenibin a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome</article-title>
          <source>Thyroid</source>
          <year>2014</year>
          <volume>24</volume>
          <issue>6</issue>
          <fpage>1062</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1089/thy.2013.0571</pub-id>
          <pub-id pub-id-type="pmid">24499195</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petramala</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cotesta</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sapienza</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zinnamosca</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Moroni</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>di Marzio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>De Toma</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Letizia</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>A case of acute aortic dissection type B associated with Cushing&#x2019;s syndrome</article-title>
          <source>J Clin Med Res</source>
          <year>2009</year>
          <volume>1</volume>
          <fpage>50</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">22505966</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marinis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yiallourou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Samanides</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dafnios</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Anastasopoulos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vassiliou</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Theodosopoulos</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Intussusception of the bowel in adults: A review</article-title>
          <source>World J Gastroenterol</source>
          <year>2009</year>
          <volume>15</volume>
          <issue>4</issue>
          <fpage>407</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.3748/wjg.15.407</pub-id>
          <pub-id pub-id-type="pmid">19152443</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vernino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Low</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Fealey</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Farrugia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lennon</surname>
              <given-names>VA</given-names>
            </name>
          </person-group>
          <article-title>Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies</article-title>
          <source>N Eng J Med</source>
          <year>2000</year>
          <volume>343</volume>
          <fpage>847</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200009213431204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castro Cabezas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vrinten</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Burgers</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Croughs</surname>
              <given-names>RJM</given-names>
            </name>
          </person-group>
          <article-title>Central diabetes insipidus and Cushing&#x2019;s syndrome due to ectopic ACTH production by disseminated small cell lung cancer: A case report</article-title>
          <source>Neth J Med</source>
          <year>1998</year>
          <volume>53</volume>
          <fpage>32</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/S0300-2977(98)00051-5</pub-id>
          <pub-id pub-id-type="pmid">9718940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Grogan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Small-Cell lung cancer presenting as diabetes insipidus and Cushing&#x2019;s syndrome</article-title>
          <source>Pituitary</source>
          <year>2005</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>105</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-005-3308-1</pub-id>
          <pub-id pub-id-type="pmid">16195775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quinkler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Bumke-Vogt</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grossmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gruber</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Oelkers</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Diederich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ba&#xA8;hr</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor</article-title>
          <source>Eur J Endocrinol</source>
          <year>2002</year>
          <volume>146</volume>
          <fpage>789</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.0.1460789</pub-id>
          <pub-id pub-id-type="pmid">12039699</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jonklaas</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Danielsen</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor concentrations but not on EC<sub>50</sub> values</article-title>
          <source>Steroids</source>
          <year>2007</year>
          <volume>72</volume>
          <issue>6&#x2013;7</issue>
          <fpage>600</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.steroids.2007.03.012</pub-id>
          <pub-id pub-id-type="pmid">17509631</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krasowski</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Drees</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Maakestad</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Blau</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Ekins</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimentional molecular similarity prediction</article-title>
          <source>BMC Clin Pathol</source>
          <year>2014</year>
          <volume>14</volume>
          <fpage>33</fpage>
          <pub-id pub-id-type="doi">10.1186/1472-6890-14-33</pub-id>
          <pub-id pub-id-type="pmid">25071417</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zengerling</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Streicher</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schrader</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Schrader</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nitzsche</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cronauer</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Hopfner</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells</article-title>
          <source>Int J Mol Sci</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>11530</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.3390/ijms130911530</pub-id>
          <pub-id pub-id-type="pmid">23109869</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>EK</given-names>
            </name>
            <name>
              <surname>Yun</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Won</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>EK</given-names>
            </name>
          </person-group>
          <article-title>Recurrent hypoglycemia triggered by sorafenib therapy in a patient with hemangiopericytoma</article-title>
          <source>Endocrinol Metab</source>
          <year>2014</year>
          <volume>29</volume>
          <fpage>202</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.3803/EnM.2014.29.2.202</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lennon</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Kryzer</surname>
              <given-names>GE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes</article-title>
          <source>N Engl J Med</source>
          <year>1995</year>
          <volume>332</volume>
          <fpage>1467</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199506013322203</pub-id>
          <pub-id pub-id-type="pmid">7739683</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Titulaer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Wirtz</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Kuks</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Schelhaas</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>van der Kooi</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Faber</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>van der Pol</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>de Visser</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sillevis Smitt</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Verschuuren</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>The Lambert-Eaton myasthenic syndrome 1988&#x2013;2008: A clinical picture in 97 patients</article-title>
          <source>J Neuroimmunol</source>
          <year>2008</year>
          <volume>201&#x2013;202</volume>
          <fpage>153</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jneuroim.2008.05.025</pub-id>
          <pub-id pub-id-type="pmid">18644631</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crone</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Vissing</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome</article-title>
          <source>Clin Neurophysiol</source>
          <year>2013</year>
          <volume>124</volume>
          <fpage>1889</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clinph.2013.02.115</pub-id>
          <pub-id pub-id-type="pmid">23643575</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>AI</given-names>
            </name>
          </person-group>
          <article-title>Procalcitonin: Uses in the clinical laboratory for the diagnosis of sepsis</article-title>
          <source>Labmed</source>
          <year>2020</year>
          <volume>41</volume>
          <issue>3</issue>
          <fpage>173</fpage>
          <lpage>7</lpage>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaczka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mikosinski</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fendker</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Celnik</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pomorski</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection</article-title>
          <source>Adv Cli Exp Med</source>
          <year>2012</year>
          <volume>21</volume>
          <issue>2</issue>
          <fpage>169</fpage>
          <lpage>78</lpage>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schumm</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pfeifer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuethe</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Figulla</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>An unusual case of progressive shock and highly elevated procalcitonin concentration</article-title>
          <source>Am J Crit Care</source>
          <year>2010</year>
          <volume>1</volume>
          <issue>19</issue>
          <fpage>96</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.4037/ajcc2009805</pub-id>
          <pub-id pub-id-type="pmid">19304564</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moura</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Cavaco</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Pinto</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Leite</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2011</year>
          <volume>96</volume>
          <fpage>E863</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2010-1921</pub-id>
          <pub-id pub-id-type="pmid">21325462</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lam</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Ringel</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Kloos</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Prior</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Knopp</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <fpage>2323</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.25.0068</pub-id>
          <pub-id pub-id-type="pmid">20368568</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="other">Gorospe EC and Badamas J. Acute liver failure secondary to metastaic medullary thyroid cancer. Case Report in Hepatology. Volume 2011, Article ID 603757, 4 pages. Doi:10.1155/2011/603757.</mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">Van Hootegem A, Verslype C, Van Steenbergen W. Sorafenib-induced liver failure: A case report and review of the literature. Case Reports in Hepatology Volume 2011, Article ID 941395, 4 pages.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
